George Abercrombie

George Abercrombie

At a Glance
    Chairman of the Board/Director, Biocryst Pharmaceuticals Inc
    Director, Ocera Therapeutics Inc
  • Age: 57
Profile

George B. Abercrombie was appointed to the Board in October 2011 and was elected Chairman of the Board in May 2013. Mr. Abercrombie has over 30 years of experience as a business leader in the pharmaceutical industry. He most recently served from 2001 to 2009 as the President and Chief Executive Officer of Hoffmann-La Roche Inc., a pharmaceutical company, where he was responsible leading operations in both the U.S. and Canada. During his tenure, Mr. Abercrombie also served as a member of the Roche Pharmaceutical Executive Committee, which was responsible for developing and implementing global strategy for the Pharmaceuticals Division. In 1993, Mr. Abercrombie joined Glaxo Wellcome Inc. as Vice President and General Manager of the Glaxo Pharmaceuticals Division, and was later promoted to Senior Vice President, U.S. Commercial Operations. Prior to joining Glaxo, he spent over ten years at Merck & Co., Inc., where he gained experience in sales and marketing, executive sales management and business development. Mr. Abercrombie began his career as a pharmacist after receiving a bachelor's degree in pharmacy from the University of North Carolina at Chapel Hill, and later earned an MBA from Harvard University. Mr. Abercrombie currently serves as Chairman of the Board of Brickell Biotech and is a member of the Board of Directors of Physicians Interactive. He formerly served on the Boards of Directors of Inspire Pharmaceuticals, Inc., Ziopharm Oncology, Inc. and Tranzyme Pharma. Additionally, he is Vice-Chairman of the Board of Directors of Project HOPE and an Adjunct Professor at Duke University's Fuqua School of Business. He previously served on the Executive Committee and Board of Directors of the Pharmaceutical Research & Manufacturers of America (PhRMA), as well as on the Board of the Johns Hopkins School of Hygiene and Public Health. [...] more

Ocera Therapeutics Inc
Director Compensation for 2013
Fees earned or paid in cash $20,000
Total Compensation $20,000
Biocryst Pharmaceuticals Inc
Director Compensation for 2013
Fees earned or paid in cash $54,500
Option awards (in $) $18,305
Total Compensation $72,805
Stock Ownership for 2014
Number of shares owned 10,000
Inspire Pharmaceuticals Inc
ZIOPHARM Oncology Inc
Stock Ownership for 2010
Number of shares owned 25,000
Financial data provided by